The role of cytokines in toxoplasmosis.
Infection with Toxoplasma gondii is normally asymptomatic, but as a consequence of the AIDS epidemic the incidence of symptomatic disease and especially toxoplasmic encephalitis (TE) has grown in frequency. The high frequency of adverse reactions to conventional therapeutic regimens for toxoplasmosis highlight the need to develop new strategies for the management of this disease. The importance of cytokines in resistance against T. gondii has been shown primarily in murine models of toxoplasmosis and a number of cytokines (e.g., IFN-gamma, TNF-alpha, IL-2 and IL-12) have been proposed for trials in patients with TE. One mechanism by which these cytokines produce their effects is through stimulation of macrophages and/or NK cells. However, there are problems with immunological intervention in immunocompromised patients with TE since the infection is present primarily in the central nervous system (CNS), an immunoprivileged site, and because certain cytokines may down regulate the immune response. While much valuable information has been obtained from studies conducted in immunocompetent strains of mice their relevance to an immunocompromised host is unknown. The development of genetically altered mice with immune deficiencies offers promising new models that may allow for more rational development of new treatment regimens.
Hunter
C A
CA
Department of Medicine, Stanford University School of Medicine, California.
Subauste
C S
CS
Remington
J S
JS
D017088:AIDS-Related Opportunistic Infections / Q000276:immunology / Q000628:therapy; D000163:Acquired Immunodeficiency Syndrome / Q000276:immunology; D000818:Animals; D016207:Cytokines / Q000276:immunology* / Q000627:therapeutic use*; D006801:Humans; D016867:Immunocompromised Host; D007167:Immunotherapy; D014122:Toxoplasma; D014123:Toxoplasmosis / Q000276:immunology* / Q000628:therapy*; D014124:Toxoplasmosis, Animal / Q000276:immunology / Q000628:therapy
D016207:Cytokines